Skip to main content
Clinical Trials/NCT00004911
NCT00004911CompletedPhase 1

A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy

Northwestern University2 sites in 1 countryStarted: January 1, 2000Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Completed
Locations
2

Study Overview

Brief Summary

RATIONALE: The use of endoscopy to place a metal stent in the large intestine is less invasive than surgery for treating cancer-related bowel obstruction and may have fewer side effects and improve recovery.

PURPOSE: Phase I/II trial to study the effectiveness of endoscopic placement of a metal stent in treating patients who have cancer-related bowel obstruction.

Detailed Description

OBJECTIVES:

  • Determine the objective response and clinical outcome in patients with colonic obstruction secondary to malignancy treated with enteral Wallstents.
  • Evaluate the efficacy and safety of this treatment in these patients.
  • Evaluate the quality of life of these patients after enteral Wallstent placement.

OUTLINE: All patient undergo a colonoscopy, followed by placement of an enteral Wallstent through an endoscope under fluoroscopic guidance into the large intestine.

Quality of life is assessed at 48 hours and 6 months after the procedure.

Patients are followed at 48 hours, 30 days, 6 months, and then yearly thereafter until death.

Study Design

Study Type
Interventional
Primary Purpose
Supportive Care

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • DISEASE CHARACTERISTICS:
  • Endoscopically confirmed localized tumor as the cause of colonic obstruction
  • All primary tumor types are eligible
  • No prior colonic Wallstents
  • Must have symptoms of gastrointestinal obstruction, including:
  • Inability to move bowels, absence of flatus, nausea/vomiting, abdominal pain, or diarrhea
  • PATIENT CHARACTERISTICS:
  • 18 and over
  • Performance status:
  • Life expectancy:
  • Not specified
  • Hematopoietic:
  • Platelet count greater than 50,000/mm^3
  • INR no greater than 1.5 times upper limit of normal
  • Not specified
  • Cardiovascular:
  • No cardiac condition
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No significant active infection (e.g., pneumonia, peritonitis, wound abscess) that would preclude endoscopy
  • No other serious concurrent illness
  • No uncontrolled metabolic disease (e.g., diabetes or hypothyroidism)
  • No dementia, psychiatric disorder, or altered mental status that would preclude compliance
  • History of other neoplastic disease allowed
  • Veterans Administration patients are not eligible
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy:
  • Not specified
  • Chemotherapy:
  • Prior or concurrent chemotherapy allowed
  • Endocrine therapy:
  • Not specified
  • Radiotherapy:
  • Prior or concurrent radiotherapy allowed
  • At least 3 weeks since prior surgery and recovered

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials